title: The side effects of gonadotropin releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty.
abstract: Treatment of central precocious puberty (CPP) is the administration of GnRH analogs. Metabolic syndrome comprised metabolic disturbances that confer increased risk of (CVD) diabetes mellitus (DM) and cardiovascular disease. This study is a longitudinal prospective study in pediatric endocrinology clinic. 30 non-obese children with idiopathic CPP were involved. Total body weight, height, blood pressure, BMI and waist circumference of the patients along with their triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), fasting plasma sugar (FPS) were evaluated at the beginning and during 3 and 6 months GnRH analog therapy. All of the patients involved in this study were female with age 9.5±1.02 years. Waist circumference, weight and BMI were 69.3 cm, 37.21 kg, and 19.13 kg/cm(2) before therapy and 72.25 cm, 40.11 kg, and 19.54 kg/m(2) 6 months after therapy respectively. Mean systolic and diastolic blood pressure of the patients before therapy was 96.83 mmHg, 66mmHg and after 6 months therapy was 98.66 mmHg, 89.63 mmHg respectively. Mean TG, LDL, HDL and FPS were 90.06 mg/dl, 91.6 mg/dl, 43.7 mg/dl and 89.6 mg/dl before therapy and 96.4 mg/dl, 93.1 mg/dl, 44.7 mg/dl and 91.36 after 6 months therapy respectively. GnRH analog therapy doesn't cause metabolic syndrome after 3 and 6 month therapy but it may cause hyperlipidemia and central obesity.
authors: Department of Pediatric Endocrinology, Student Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
authors: Zohreh
authors: Z
authors: Karamizadeh
authors: Mahmoodreza
authors: M
authors: Tabebordbar
authors: Forough
authors: F
authors: Saki
authors: Hamdollah
authors: H
authors: Karamifar
authors: Gholamhossein
authors: G
authors: Amirhakimi
mesh_terms: D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001827:Body Height / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002648:Child; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects* / Q000031:analogs & derivatives; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D056128:Obesity, Abdominal / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D011446:Prospective Studies; D011629:Puberty, Precocious / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000009:adverse effects* / Q000031:analogs & derivatives; D055105:Waist Circumference
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D008055:Lipids; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone